Chapter 4: Evidence for the Early Use of Ablation and AADs Post-Ablation

Area of Science:

• Cardiology
• Electrophysiology

Background:

• Atrial fibrillation (AF) management involves catheter ablation and antiarrhythmic drugs (AADs), used individually or combined.
• Shared decision-making is crucial for selecting the optimal therapeutic strategy for AF patients.

Approach:

• Review of data from key trials including CABANA, STOP AF, and EARLY AF, analyzing ablation versus AADs for AF treatment.
• Discussion of analytical complexities in the CABANA trial, such as protocol adherence, treatment crossovers, and concomitant AAD use.

Key Points:

• The CABANA trial's intent-to-treat analysis did not show ablation superiority, but per-protocol analyses indicated better AF recurrence prevention with ablation.
• Ablation demonstrated superiority over AADs alone in reducing recurrent AF in multiple trials.
• Combination therapy with AADs post-ablation is common, with 40-50% of patients using them at one year.

Conclusions:

• Catheter ablation is more effective than AADs alone for preventing AF recurrence.
• Combined ablation and AAD therapy is a frequently utilized and effective strategy for managing atrial fibrillation.